...
首页> 外文期刊>Assay and drug development technologies >Discovering small molecule ligands of vascular endothelial growth factor that block VEGF-KDR binding using label-free microarray-based assays
【24h】

Discovering small molecule ligands of vascular endothelial growth factor that block VEGF-KDR binding using label-free microarray-based assays

机译:使用基于无标记微阵列的检测方法发现可阻断VEGF-KDR结合的血管内皮生长因子小分子配体

获取原文
获取原文并翻译 | 示例
           

摘要

We present here a label-free microarray-based assay platform that we used to identify inhibitors of vascular endothelial growth factor (VEGF)-kinase-insertion domain receptor (KDR) binding. Supported by a combination of special ellipsometry-based optical detection and small molecule microarrays (SMM), this platform consists of three assays: (1) the first assay detects binding of a target protein with SMM and identifies ligands to the protein as inhibitor candidates; (2) the second assay detects binding of a receptor protein with identical SMM and subsequent binding of the target protein (a sandwich assay) to identify the ligands to the receptor protein that do not interfere with the target-receptor binding; (3) the third assay detects binding of the target protein to the receptor protein in the presence of the ligands of the target protein identified from the first assay, with the receptor protein immobilized to a solid surface through the ligands identified in the second assay, to yield dose-response curves. Using this platform, we screened 7,961 compounds from the National Cancer Institute and found 12 inhibitors to VEGF-KDR (VEGFR2) interactions with IC50 ranging from 0.3 to 60 μM. The inhibitory potency of these inhibitors found in the microarray-based assay was confirmed by their inhibition of VEGF-induced VEGFR2 phosphorylation in a cell-based assay.
机译:我们在这里提出了一个无标签的基于微阵列的分析平台,我们用来确定血管内皮生长因子(VEGF)-激酶插入域受体(KDR)结合的抑制剂。该平台由特殊的基于椭偏仪的光学检测和小分子微阵列(SMM)共同支持,包括三个检测方法:(1)第一个检测方法可检测靶蛋白与SMM的结合,并鉴定该蛋白的配体作为抑制剂候选物; (2)第二种测定法检测受体蛋白质与相同的SMM的结合以及随后与靶蛋白质的结合(夹心测定),以鉴定不干扰靶-受体结合的配体与受体蛋白质; (3)第三次测定在从第一次测定中鉴定出的靶蛋白配体存在的情况下检测靶蛋白与受体蛋白的结合,并通过第二次测定中鉴定出的配体将受体蛋白固定在固体表面上,得出剂量反应曲线。使用该平台,我们从美国国立癌症研究所筛选了7,961种化合物,发现12种VEGF-KDR(VEGFR2)相互作用的抑制剂,IC50为0.3至60μM。通过在基于细胞的测定中抑制VEGF诱导的VEGFR2磷酸化,证实了在基于微阵列的测定中发现的这些抑制剂的抑制能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号